This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Osteoarthritis  • Diabetes Mellitus  • Alert me on articles by topic

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Diabetes is a progressive disease characterized by continued decline in insulin secretion that results in worsening of glycemic control over time.¹ The study by Scroggie et al² provided evidence that the use of glucosamine-chondroitin supplementation for the treatment of osteoarthritis in patients with diabetes does not pose a significant risk to worsening glycemic control in the form of elevated hemoglobin A_1c levels.² The study included 18% of patients who were only diet controlled and a median number of 1 hypoglycemic agent per patient in the rest of the population and demonstrated excellent blood glucose control as evidenced by the mean glycohemoglobin level of 6.45%. The lack of negative impact of glucosamine on glycemic control may be explained by a compensatory increase in endogenous insulin secretion in response to a possible increase in insulin resistance due to glucosamine in these patients who are at a potentially early stage in the course . . . [Full Text of this Article]

Rajeev K. Jain, MD; Joseph C. McCormick, BS
Milwaukee, Wis

RELATED ARTICLE

The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-blinded, Randomized Clinical Trial
Daren A. Scroggie, Allison Albright, and Mark D. Harris
Arch Intern Med. 2003;163(13):1587-1590.
ABSTRACT | FULL TEXT